Skip to content

EBIT at other companies

Organon logo
OrganonOGN
$324M+44.0%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$84.15M-13.1%
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
$29.27M+121%
Pfizer logo
PfizerPFE
Amgen logo
AmgenAMGN
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.28B+57.5%
Enterprise value$3.36B+57.0%
P/S7.9×-1.9×

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Calculated from Arcutis Biotherapeutics, Inc.’s reported figures.

Plus components not separately reported this period.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s EBIT?
Arcutis Biotherapeutics, Inc. (ARQT) reported EBIT of -$9.09M in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s EBIT changed year-over-year?
Arcutis Biotherapeutics, Inc.'s EBIT increased by 62.9% year-over-year, from -$24.53M to -$9.09M.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s EBIT?
Over 3 years (2021 to 2024), Arcutis Biotherapeutics, Inc.'s EBIT has grown at a -14.7% compound annual growth rate (CAGR), from -$206.53M to -$128.4M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.